Tags : Amgen

Top 20

Top 20 BioPharma Companies based on 2020 Total Revenue

Despite having the global Covid-19 pandemic, the biopharma companies were involved in multiple M&A and licensing deals. The major focus of the year remains the production and distribution of vaccines to combat the COVID-19 globally All of the Biopharma companies on our list are on the front line to combat this global crisis. The top […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshots (Mar 29 – Apr 02, 2021)

Pfizer and BioNTech Report Results of BNT162b2 to Prevent COVID-19 Published: Apr 2, 2021 | Tags: Pfizer and BioNTech, Report, Results, BNT162b2, Prevent, COVID-19 Acceleron Presents Results of Sotatercept in P-II PULSAR Trial for the Treatment of Pulmonary Arterial Hypertension, Published in NEJM Published: Apr 2, 2021 | Tags: Acceleron, Presents, Results, Sotatercept, P-II PULSAR […]Read More

M&A

Amgen to Acquire Rodeo Therapeutics for ~$721M

Shots: Amgen to acquire all outstanding shares of Rodeo for a $55M upfront along with ~$666M in cash as contingent milestones The acquisition will strengthen Amgen’s inflammation portfolio with the addition of Rodeo’s 15-PGDH program Rodeo’s 15-PGDH has the potential in its preclinical studies and have clinical potential in multiple indications Click here to­ read full […]Read More

Insights+

Insights+: Breakthrough Therapy Designation by the US FDA in 2020

Breakthrough Therapy (BT) Designation is an expedited review program introduced in Section 902 of the Food and Drug Safety and Innovation Act of 2012 The Breakthrough Designation is granted to the drug candidates as monotherapy or in combination with other drugs intended to treat serious or life-threatening diseases and has shown substantial improvement over available […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshots (Mar 01 – 05, 2021)

Eli Lilly and Incyte Report Results of Olumiant (baricitinib) in P-III BRAVE-AA2 Study for Severe Alopecia Areata Published: Mar 5, 2021 | Tags: Eli Lilly and Incyte, Report, Results, Olumiant (baricitinib), P-III, BRAVE-AA2, Study, Severe, Alopecia Areata Takeda Reports NDA Submission to Import and Distribute Moderna’s mRNA-1273 in Japan Published: Mar 5, 2021 | Tags: […]Read More

M&A

Amgen to Acquire Five Prime for ~$1.9B

Shots: Amgen to acquire all of the outstanding shares of Five Prime for $38.00 /share in cash, representing an equity value of ~ $1.9B. The transaction is expected to close in Q2’21 The acquisition will add Five Prime’s innovative pipeline to Amgen thus expanding its oncology portfolio and supports its international expansion strategy Five Prime’s […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshots (Feb 22- 26, 2021)

Regeneron Reports IDMC Clearance of Efficacy for REGEN-COV (Casirivimab + Imdevimab) in P-III COVID-19 Outpatient Outcomes Trial Published: Feb 26, 2021 | Tags: Regeneron, Reports, IDMC, Clearance, Efficacy, REGEN-COV (Casirivimab + Imdevimab), P-III, COVID-19, Outpatient, Outcomes, Trial Daiichi Sankyo Collaborates with LYSA-LYSARC-CALYM for Valemetostat in Patients with R/R B-Cell Lymphoma Published: Feb 26, 2021 | […]Read More